NATICK, Mass., Jan. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
NATICK, Mass., Dec. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) today announced the pricing of a public offering of $2 billion aggregate principal amount of its senior...
Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets NATICK, Mass. and LONDON, Nov. 20...
Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets NATICK, Mass. and LONDON, Nov. 20...
Three models of stenting system now available for palliative treatment of malignant common bile duct strictures NATICK, Mass., Oct. 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation...
NATICK, Mass., Sept. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference, September 14-15. Ray...
NATICK, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in the Thomas Weisel Partners 2009 Health Care Conference, September 9...
NATICK, Mass. and BARCELONA, Sept. 1 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) today announced long-term data from the Prevention of Sudden Cardiac Death II registry...
Results of landmark heart failure trial published by New England Journal of Medicine and presented at ESC NATICK, Mass., and BARCELONA, Spain, Sept. 1 /PRNewswire/ -- Boston Scientific...
NATICK, Mass., Aug. 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) today announced the schedule of the Company's major events and news announcements for the European...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales